Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (<i>R</i>)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (PF-06821497)Pei‐Pei Kung, Martin P. Edwards, Cody Krivacic et al.|Journal of Medicinal Chemistry|2017Cited by 129
Discovery of 1-{(3<i>R</i>,4<i>R</i>)-3-[({5-Chloro-2-[(1-methyl-1<i>H</i>-pyrazol-4-yl)amino]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR MutantsHengmiao Cheng, Ru Zhou, Sajiv K. Nair et al.|Journal of Medicinal Chemistry|2016Cited by 93
Practical Singly and Doubly Electrophilic Aminating Agents: A New, More Sustainable Platform for Carbon–Nitrogen Bond FormationPadmanabha V. Kattamuri, László Kürti, Jun Yin et al.|Journal of the American Chemical Society|2017Cited by 90
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancerShikhar Sharma, Meghan Hattarki, Chi‐Yeh Chung et al.|Cell chemical biology|2023Cited by 72
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2 <i>H</i> )-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) InhibitorsPei‐Pei Kung, Martin P. Edwards, Eugene Rui et al.|Journal of Medicinal Chemistry|2016Cited by 70